Total Mark
91
Above 70 is preferred
Stock Analysis
Growth Potential | 100 | |
---|---|---|
Profitability | 88 | |
Financial Strength | 83 | |
Q4 2019 Result | 92 | |
Q3 2019 Result | 96 | |
Result 2019 | 83 |
Growth Estimate
20 Estimate | 21 Estimate | |
---|---|---|
Revenue Growth (%) | 36.6 | 27.6 |
EPS Growth (%) | 108.5 | 46.7 |
ROE (%) | 39.3 | 43.7 |
P/E (times) | ... | ... |
Market Analysis
Market Sentiment | 33 | |
---|---|---|
Relative Valuation | 98 | |
Being a Value Stock | 57 | |
Absolute Valuation | NA |
For more detailed information about Neurocrine Biosciences Inc, please go to Yahoo Finance